Mirum Pharmaceuticals (MIRM) News Today $41.51 +0.38 (+0.92%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period State Street Corp Grows Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)State Street Corp increased its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 19.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,793,728 shares of the company's stock after buying aDecember 18 at 3:35 AM | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $57.73 Average Price Target from AnalystsDecember 18 at 1:32 AM | americanbankingnews.comWellington Management Group LLP Raises Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Wellington Management Group LLP lifted its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 62.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,334 shares of the company's stock after purcDecember 17, 2024 | marketbeat.com741,368 Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Bought by Lord Abbett & CO. LLCLord Abbett & CO. LLC acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the third quarter, according to the company in its most recent filing with the SEC. The fund acquired 741,368 shares of the company's stock, valued at approximately $28,913,000. Lord AbbeDecember 16, 2024 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Recommendation of "Buy" by BrokeragesMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) has been given a consensus rating of "Buy" by the twelve ratings firms that are currently covering the firm, Marketbeat Ratings reports. Ten research analysts have rated the stock with a buy recommendation and two have given a strong buy rDecember 15, 2024 | marketbeat.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 10, 2024 | businesswire.comFrazier Life Sciences Management L.P. Has $256.25 Million Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Frazier Life Sciences Management L.P. boosted its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 1.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,570,392 shares of the company's stock afterDecember 10, 2024 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Purchased by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. boosted its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 5.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 328,161 shares of the company's stockDecember 9, 2024 | marketbeat.comMirum Pharmaceuticals price target raised to $74 from $69 at JMP SecuritiesDecember 6, 2024 | markets.businessinsider.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Janus Henderson Group PLCJanus Henderson Group PLC decreased its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 10.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,480,284 sharDecember 4, 2024 | marketbeat.comErste Asset Management GmbH Buys New Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Erste Asset Management GmbH purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 260,000 shares of the company's stock, valued at approximDecember 2, 2024 | marketbeat.comIntech Investment Management LLC Buys Shares of 12,733 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Intech Investment Management LLC bought a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 12,733 shares of the company's stock, valued at approximately $497,000. A numberDecember 2, 2024 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Eventide Asset Management LLCEventide Asset Management LLC lowered its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 24.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 3,445,363 shares of the company's stock after selling 1,119,457 shares duringNovember 29, 2024 | marketbeat.comLoomis Sayles & Co. L P Purchases New Shares in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Loomis Sayles & Co. L P purchased a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 499,316 shares of the company's stock,November 27, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Purchases 21,526 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 46.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 67,November 25, 2024 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Annexon Biosciences (ANNX), Mirum Pharmaceuticals (MIRM)November 21, 2024 | markets.businessinsider.comPhocas Financial Corp. Has $1.48 Million Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)Phocas Financial Corp. lessened its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 37.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 37,889 shares of the company's stock after selling 2November 20, 2024 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of "Buy" by BrokeragesShares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have been given a consensus rating of "Buy" by the twelve brokerages that are presently covering the firm, Marketbeat.com reports. Ten analysts have rated the stock with a buy rating and two have assigned a strong buy rating toNovember 20, 2024 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by First Turn Management LLCFirst Turn Management LLC decreased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 7.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 647,611 shares of the company's stock afNovember 19, 2024 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 4.6% After Insider SellingMirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Down 4.6% on Insider SellingNovember 18, 2024 | marketbeat.comMIRM FY2024 EPS Estimate Raised by Cantor FitzgeraldMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2024 EPS estimates for shares of Mirum Pharmaceuticals in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the companyNovember 18, 2024 | marketbeat.comJolanda Howe Sells 2,500 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockNovember 16, 2024 | insidertrades.comInsider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 2,500 Shares of StockMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $47.10, for a total value of $117,750.00. Following the completion of the transaction, the senior vice president now directly owns 2,426 shares of the company's stock, valued at approximately $114,264.60. This trade represents a 50.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.November 15, 2024 | marketbeat.comHC Wainwright Has Optimistic Outlook of MIRM FY2024 EarningsMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Research analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Mirum Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst E. Arce now anticipates that the companNovember 15, 2024 | marketbeat.comWhat is Leerink Partnrs' Forecast for MIRM FY2024 Earnings?Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Investment analysts at Leerink Partnrs boosted their FY2024 earnings estimates for shares of Mirum Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 12th. Leerink Partnrs analyst M. Foroohar now foreNovember 15, 2024 | marketbeat.comMirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver MeetingNovember 15, 2024 | finance.yahoo.comMirum Pharmaceuticals Positioned for Growth: Strong Q3 Performance and Strategic Acquisitions Drive Positive OutlookNovember 14, 2024 | markets.businessinsider.comEvercore ISI Initiates a Buy Rating on Mirum Pharmaceuticals (MIRM)November 14, 2024 | markets.businessinsider.comQ3 EPS Estimate for Mirum Pharmaceuticals Cut by AnalystMirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Equities researchers at HC Wainwright reduced their Q3 2025 earnings per share estimates for shares of Mirum Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst E. Arce now expects that the compNovember 14, 2024 | marketbeat.comMirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ...November 14, 2024 | finance.yahoo.comPromising Outlook for Mirum Pharmaceuticals: Buy Rating Justified by Strong Performance and Strategic InitiativesNovember 13, 2024 | markets.businessinsider.comMirum Pharmaceuticals price target raised to $68 from $65 at CitiNovember 13, 2024 | markets.businessinsider.comMirum Pharmaceuticals Reports Strong Q3 Sales GrowthNovember 13, 2024 | markets.businessinsider.comMirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | finanznachrichten.deMirum Pharmaceuticals (NASDAQ:MIRM) Issues Earnings ResultsMirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 43.47% and a negative net margin of 40.34%. The firm had revenue of $90.38 million during the quarter, compared to analysts' expectations of $81.99 million. During the same period last year, the business posted ($0.57) earnings per share. The company's revenue for the quarter was up 89.4% compared to the same quarter last year.November 13, 2024 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $50.00 at Robert W. BairdRobert W. Baird boosted their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an "outperform" rating in a research note on Wednesday.November 13, 2024 | marketbeat.comMirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comMirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week High - Here's What HappenedMirum Pharmaceuticals (NASDAQ:MIRM) Hits New 1-Year High - Time to Buy?November 12, 2024 | marketbeat.comGSA Capital Partners LLP Buys 51,482 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)GSA Capital Partners LLP lifted its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 791.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 57,985 shares of the company's stock after purchasing an addiNovember 12, 2024 | marketbeat.comMirum Pharmaceuticals (MIRM) Scheduled to Post Earnings on TuesdayMirum Pharmaceuticals (NASDAQ:MIRM) will be releasing earnings before the market opens on Tuesday, November 12, Zacks reports.November 5, 2024 | marketbeat.comAlphaCentric Advisors LLC Decreases Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)AlphaCentric Advisors LLC decreased its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 29.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,000 shares of the companNovember 5, 2024 | marketbeat.comMirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024November 4, 2024 | businesswire.comMirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual MeetingOctober 31, 2024 | finance.yahoo.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Buy" by AnalystsShares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) have been assigned an average rating of "Buy" from the twelve brokerages that are currently covering the firm, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy rating and two have given aOctober 26, 2024 | marketbeat.comMirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales GrowthOctober 23, 2024 | msn.comAQR Capital Management LLC Sells 23,721 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)AQR Capital Management LLC decreased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 74.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,294 shares of the company's stock after selling 23,721 sOctober 17, 2024 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company lessened its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 49.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 22,134 shares of the company's stock after seOctober 15, 2024 | marketbeat.comMirum Pharmaceuticals’ Volixibat Garners Buy Rating Amidst Breakthrough Therapy Designation and Promising Trial ResultsOctober 11, 2024 | markets.businessinsider.comMirum Pharmaceuticals (NASDAQ:MIRM) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Friday.October 11, 2024 | marketbeat.comMirum Pharmaceuticals' Volixibat Gets Breakthrough Therapy Designation from FDAOctober 10, 2024 | marketwatch.com Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address I was wrong. Dead wrong. (Ad)I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. MIRM Media Mentions By Week MIRM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MIRM News Sentiment▼1.290.61▲Average Medical News Sentiment MIRM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MIRM Articles This Week▼54▲MIRM Articles Average Week Get Mirum Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Revolution Medicines News Today Lantheus News Today Legend Biotech News Today Nuvalent News Today Blueprint Medicines News Today Elanco Animal Health News Today Cytokinetics News Today TG Therapeutics News Today Viking Therapeutics News Today BridgeBio Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MIRM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mirum Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MIRM Stock Alerts